Oisin Biotechnologies develops genetic therapies utilizing Fusogenix™ Proteo-Lipid Vehicle technology to deliver DNA and RNA payloads for the treatment of age-related diseases. Their pipeline includes programs targeting frailty by promoting muscle growth, selectively eliminating fat cells, and removing senescent cells.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AFounders
Product
Problem
Age-related diseases and frailty are driven by factors such as muscle loss, accumulation of senescent cells, and excess fat tissue. Current treatments often lack targeted delivery mechanisms and may not address the underlying genetic causes of these conditions.
Solution
Oisin Biotechnologies develops genetic therapies for age-related diseases using its Fusogenix™ Proteo-Lipid Vehicle (PLV) technology. This non-viral delivery system enables targeted delivery of DNA and RNA payloads to address the genetic drivers of aging. The company's pipeline includes programs focused on promoting muscle growth to combat frailty, selectively eliminating fat cells, and removing senescent cells that contribute to age-related decline. The PLV technology facilitates extensive biodistribution beyond the liver and allows for safe, repeated dosing.
Target Audience
The primary target audience includes individuals at risk of or affected by age-related diseases, as well as researchers and clinicians focused on developing therapies for aging and frailty.
Features
- Fusogenix™ Proteo-Lipid Vehicle (PLV) technology for targeted delivery of genetic payloads.
- Non-viral delivery system enabling safe and repeated dosing.
- Therapies designed to promote muscle growth and combat frailty.
- Treatments focused on selectively eliminating fat cells.
- Programs aimed at removing senescent cells.
- Extensive extrahepatic biodistribution for DNA and RNA payloads.